Evidence map›Paper›PMID 34564026›Full record

ArticleCancer epidemiology2021

A prospective study of inflammatory biomarkers and growth factors and risk of glioma in the UK Biobank.

David J Cote, Jordan H Creed, Claudine M Samanic, Travis A Gerke, Meir J Stampfer, Stephanie A Smith-Warner, Kathleen M Egan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Recent Developments in Blood Biomarkers in Neuro-oncology.Current neurology and neuroscience reports · 2023
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

David J CoteChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States; Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: david_cote@hms.harvard.edu.
Jordan H CreedDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States. Electronic address: Jordan.H.Creed@moffitt.org.
Claudine M SamanicDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Travis A GerkeDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Meir J StampferChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Stephanie A Smith-WarnerDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Kathleen M EganDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Moffitt Cancer Center · USBrigham and Women's Hospital · USHarvard University · US

Funding

Etiology of glioma and glioblastomaF30CA235791 · NCI · HARVARD MEDICAL SCHOOL · PI COTE, DAVID JAMES · 2019 to 2020
$85k
Medical Research Council MC_PC_17228Medical Research Council MC_QA137853NCI NIH HHS F30 CA235791
6 · The paper itself

Abstract

purposeThe role of growth factors and inflammation in the onset of glioma is poorly understood, and conflicting reports of associations of circulating IGF-1 and inflammatory biomarkers with glioma risk exist in the literature. We examined associations between C-reactive protein (CRP), white blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR), and insulin-like growth factor-1 (IGF-1) and glioma risk in the UK Biobank cohort.

methodsHazard ratios (HR) and 95% confidence intervals (CI) for glioma according to circulating biomarkers concentrations were calculated using Cox proportional hazards regression, adjusted for age, sex, race, and education. Analyses were conducted separately for glioma overall and by glioma subtype.

resultsWe identified 417 incident glioma cases among 428,537 participants with 3,255,815 person-years of follow up. Weak, non-significant associations were observed with increasing levels of these biomarkers for risk of glioma overall or by glioma subtype. Among women only, IGF-1 in the highest quartile was positively associated with glioma risk compared to the lowest quartile (HR=1.64, 95%CI: 1.03-2.60, p-trend=0.08), as was NLR (HR=1.54, 95%CI: 1.00-2.39, p-trend=0.05).

conclusionIn this prospective cohort, we found no significant associations between the inflammatory biomarkers CRP and WBC and the development of glioma. NLR and IGF-1 were associated with risk in women, but not men. When considered with previous studies, further investigation of NLR and IGF-1 as markers of glioma risk appears warranted, particularly in women.

Indexed as

Biological Specimen BanksGliomaBiomarkersFemaleHumansProspective StudiesRisk FactorsUnited KingdomBiomarkersCohortEpidemiologyGlioblastomaGliomaInflammationUK biobank

Identifiers

PMID34564026
PMCPMC8627477
OpenAlexW3202821859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.